Where Will Kalvista Pharmaceuticals Inc (KALV) Stock Go Next After It Has Gained 6.61% in a Week?

Overall market sentiment has been high on Kalvista Pharmaceuticals Inc (KALV) stock lately. KALV receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Kalvista Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on KALV!

See Full KALV Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With KALV Stock Today?

Kalvista Pharmaceuticals Inc (KALV) stock is trading at $8.23 as of 11:45 AM on Monday, Nov 20, a rise of $0.11, or 1.35% from the previous closing price of $8.12. The stock has traded between $8.00 and $8.67 so far today. Volume today is below average. So far 106,239 shares have traded compared to average volume of 243,382 shares. To screen for more stocks like Kalvista Pharmaceuticals Inc click here.

More About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. Click Here to get the full Stock Report for Kalvista Pharmaceuticals Inc stock.